Business
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
SAN JOSE, Calif., July 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., July 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) (\"Anixa\"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. \n\n \n \n \n \n \n \n\n \nThe patent is titled, \"Breast Cancer Vaccine,\" and the lead inventor is Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. This patent is in the family of the originally granted patent, and it covers additional intellectual property related to Anixa's breast cancer vaccine technology.\n\"We are pleased to receive this notice of allowance from the USPTO, confirming additional protection of the breast cancer vaccine technology,\" stated Dr. Amit Kumar, Chairman and CEO of Anixa. \"This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer (\"TNBC\"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin. With our partners at Cleveland Clinic, we are currently performing clinical testing of this vaccine, and hope to have preliminary results by year end.\"\nAbout Triple-Negative Breast CancerOne in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.\nAbout Anixa Bioscience's Breast Cancer VaccineAnixa's investigational vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become \"retired\" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present...